Clinical Data Novo, Lilly trade oral GLP-1 data readouts at ECO PharmaphorumNovo Nordisk trumpets oral Wegovy efficacy data at ECO, while Lilly builds the case for switching to Foundayo in maintenance phase after injectables.Metabolic & GLP-1Read full story pharminent May 13, 2026 (Last updated: May 16, 2026) Pharmaphorum Novo Nordisk trumpets oral Wegovy efficacy data at ECO, while Lilly builds the case for switching to Foundayo in maintenance phase after injectables. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Isomorphic Labs receives $2.1bn for AI drug developmentNext: UAE approves AstraZeneca’s Baxfendy for hypertension Related Stories Clinical Data Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs pharminent July 14, 2026 Clinical Data Major trial launched to explore GLP-1 benefit in dementia pharminent July 13, 2026 Clinical Data GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China pharminent July 10, 2026
